Gubra releases another record year-end report - bottom-line has increased by 69 percent

Biotech and contract research firm Gubra has smashed its previous records with its latest year-end report, which shows 69 percent profit growth to total DKK 27.7 million (USD 4 million).

Henrik Blou, CEO of Gubra Photo: Gubra/ PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles